E Ezan

RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.

P Corvol, A Yiotakis, V Dive, 2001, The Journal of pharmacology and experimental therapeutics.

Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.

C Fraser, C. Junot, E. Ezan, 1999, Journal of the American College of Cardiology.

Practical method for optimizing radioimmunoassay detection and precision limits.

E. Ezan, E Ezan, F. Dray, 1991, Clinical chemistry.